EXPAND 🖟

Important Safety Information

TECFIDERA Warnings and Precautions include: Anaphylaxis and Angioedema, Progressive Multifocal Leukoencephalopathy, Lymphopenia, Liver Injury, and Flushing.




TECFIDERA Clinical Trials

THE DEFINE* TRIAL

The DEFINE trial included patients who were new to MS treatment and patients who were MS treatment-experienced¹



A 2-year, randomized, double-blind, placebo-controlled study in 1234 patients with relapsing-remitting multiple sclerosis (RRMS)²



Randomization^{2†}



One 120 mg capsule twice a day for the first 7 days, followed by an increase to one 240 mg capsule twice a day

Placebo n=408



Endpoints²

Primary

Proportion of patients relapsed (PPR)

Additional

- Annualized relapse rate (ARR)
- Time to confirmed disability progression
- Number of new or newly enlarging T2 hyperintense lesions
- Number of Gd+ lesions
- Number of new T1 hypointense lesions

Key inclusion criteria²

Experienced at least 1 relapse over the year preceding the trial

OR

Had a brain magnetic resonance imaging (MRI) scan demonstrating at least 1 gadolinium-enhancing (Gd+) lesion within 6 weeks of randomization

AND

An Expanded Disability Status Scale (EDSS) score ranging from 0 to 5

Key exclusion criteria¹

- Interferon-beta or glatiramer acetate within 3 months of randomization
- An infusion disease-modifying therapy (DMT) within 6 months of randomization
- Primary progressive multiple sclerosis or secondary progressive multiple sclerosis
- Any major disease that would preclude participation in a clinical trial

Evaluations²



Neurological evaluations

Performed at baseline, every 3 months, and at time of suspected relapse

MRI evaluations

Performed in 44% of patients at baseline, month 6, and years 1 and 2

69% of patients treated with TECFIDERA BID completed 96 weeks of treatment (compared to 65% of patients taking placebo)²


THE CONFIRM[‡] TRIAL

The CONFIRM trial included patients who were new to MS treatment and patients who were MS treatment-experienced³



A 2-year, multicenter, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of TECFIDERA compared to oral placebo in 1417 patients with RRMS.

CONFIRM included an open-label comparator arm²



Randomization^{2§}

TECFIDERA (dimethyl fumarate)

PO 240 mg n=359

Placebo n=363

Open-label Comparator n=350



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

